Acquiring Company
Rosemont Pharmaceuticals
Acquired Company
Aytu BioPharma
Description
Rosemont Pharmaceuticals has entered a definitive merger agreement to acquire Aytu BioPharma through a tender offer at $2.70 per share in cash, a 41.1 per cent premium to Aytu's 30-day VWAP. The deal was unanimously approved by Aytu's board, with completion anticipated in late December 2026, subject to conditions. The acquisition will be followed by a second-step merger at the same price and supports Rosemont's US specialty pharmaceutical expansion.
Quick answer
Rosemont Pharmaceuticals is acquiring Aytu BioPharma, announced November 17, 2026. Rosemont Pharmaceuticals is based in United Kingdom.
- How much did Rosemont Pharmaceuticals pay for Aytu BioPharma?
- The deal value was not disclosed.
- What does Rosemont Pharmaceuticals do?
- Rosemont Pharmaceuticals is a specialty pharmaceutical company expanding its international and US specialty medicines business.
- Where are Rosemont Pharmaceuticals and Aytu BioPharma based?
- Rosemont Pharmaceuticals is based in United Kingdom. Aytu BioPharma is based in Denver, Colorado, United States.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Healthcare
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Sai Parenterals to acquire Bion's Rx unit (November 17, 2026)
- Gedeon Richter to acquire Mayne Pharma at $6.40/share (November 16, 2026)
- Charles River Laboratories to Acquire Bioanalysis and DMPK Operations from Frontage Holdings (November 9, 2026)
- Perth buyer acquires Mayne Pharma's Australian arm (November 8, 2026)
- Evaris Pharma to buy Mayne's Australian arm (November 6, 2026)
- ANI Pharmaceuticals offers to acquire Egetis (November 5, 2026)
Who to call at Rosemont Pharmaceuticals, and when
When Rosemont Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Rosemont Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Rosemont Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Rosemont Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Rosemont Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Aytu BioPharma?
Aytu BioPharma was acquired by Rosemont Pharmaceuticals, based in United Kingdom. The deal was reported on November 17, 2026. Rosemont Pharmaceuticals is a specialty pharmaceutical company expanding its international and US specialty medicines business. It is backed by Inflexion, a European mid-market private equity firm. Rosemont Pharmaceuticals is privately held and operates in Biotechnology.
When did Rosemont Pharmaceuticals acquire Aytu BioPharma?
Rosemont Pharmaceuticals's acquisition of Aytu BioPharma was reported on November 17, 2026. Rosemont Pharmaceuticals has entered a definitive merger agreement to acquire Aytu BioPharma through a tender offer at $2.70 per share in cash, a 41.1 per cent premium to Aytu's 30-day VWAP. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Aytu BioPharma do?
Aytu BioPharma, Inc. is a biopharmaceutical company that focuses on developing and commercializing novel products in the field of men's health, women’s health, and other underserved patient populations. It is publicly traded (AYTU), operating in Healthcare, and is based in Denver.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.